Direct effects of octreotide on osteoblast cell proliferation and function

Area of Science:

• Bone Biology and Pharmacology
• Endocrinology
• Oncology

Background:

• Octreotide (OCT), a somatostatin analog, treats acromegaly and neuroendocrine tumors (NETs) by targeting somatostatin receptors (SSTRs).
• Skeletal health is a significant concern in acromegaly and NETs due to osteopathy and bone metastasis.
• OCT's direct effects on bone cells remain largely uninvestigated.

Purpose of the Study:

• To investigate the direct effects of Octreotide (OCT) on osteoblast proliferation, differentiation, mineralization, and chemoattractant capacity.
• To elucidate the role of somatostatin receptors (SSTR2 and SSTR5) in mediating OCT's actions on bone cells.

Main Methods:

• Primary murine osteoblasts and MC3T3-E1 osteoblast cell line were used to assess OCT's effects.
• Cell proliferation, apoptosis, differentiation markers, ALP activity, and mineralization were analyzed.
• Gene expression (Alp, Runx2, Bglap, Spp1, Sost, Vegfa) and chemoattractant capacity were evaluated.

Main Results:

• OCT significantly inhibited osteoblast proliferation and increased apoptosis in MC3T3-E1 cells, mediated by SSTR2 and SSTR5.
• OCT did not affect osteoblast differentiation markers, ALP activity, or mineralization.
• OCT reduced Vegfa expression and inhibited pancreatic NET cell migration towards osteoblast-conditioned medium.

Conclusions:

• This study demonstrates Octreotide's direct inhibitory effects on osteoblast proliferation and pro-apoptotic actions.
• These findings highlight potential clinical implications for managing skeletal health in patients with acromegaly and metastatic NETs.
• Further research is warranted to fully understand OCT's role in bone metabolism and its therapeutic potential.